{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:22:10Z","timestamp":1793690530491,"version":"4.5.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s00228-020-03011-x","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T20:02:44Z","timestamp":1603137764000},"page":"291-309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Pharmacokinetic variability of phenobarbital: a systematic review of population pharmacokinetic analysis"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5142-8769","authenticated-orcid":false,"given":"Janthima","family":"Methaneethorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattawut","family":"Leelakanok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"issue":"8","key":"3011_CR1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/000992288202100801","volume":"21","author":"HR Boer","year":"1982","unstructured":"Boer HR, Gal P (1982) Neonatal seizures: a survey of current practice. Clin Pediatr 21(8):453\u2013457","journal-title":"Clin Pediatr"},{"issue":"3","key":"3011_CR2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0022-3476(74)80127-7","volume":"85","author":"A Wallin","year":"1974","unstructured":"Wallin A, Jalling B, Bor\u00e9us LO (1974) Plasma concentrations of phenobarbital in the neonate during prophylaxis for neonatal hyperbilirubinemia. J Pediatr 85(3):392\u2013397","journal-title":"J Pediatr"},{"issue":"4","key":"3011_CR3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-199529040-00005","volume":"29","author":"D Battino","year":"1995","unstructured":"Battino D, Estienne M, Avanzini G (1995) Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Clin Pharmacokinet 29(4):257\u2013286","journal-title":"Clin Pharmacokinet"},{"key":"3011_CR4","volume-title":"Clinical pharmacokinetics: ASHP","author":"JE Murphy","year":"2011","unstructured":"Murphy JE. Clinical pharmacokinetics: ASHP; 2011"},{"key":"3011_CR5","volume-title":"Basic clinical pharmacokinetics: Lippincott Williams & Wilkins","author":"ME Winter","year":"2004","unstructured":"Winter ME. Basic clinical pharmacokinetics: Lippincott Williams & Wilkins; 2004"},{"issue":"7\u20138","key":"3011_CR6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/1060028089023007-806","volume":"23","author":"NM Graves","year":"1989","unstructured":"Graves NM, Holmes GB, Kriel RL, Jones-Saete C, Ong B, Ehresman DJ (1989) Relative bioavailability of rectally administered phenobarbital sodium parenteral solution. Dicp. 23(7\u20138):565\u2013568","journal-title":"Dicp."},{"issue":"2","key":"3011_CR7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0928-0987(00)00145-7","volume":"12","author":"D Touw","year":"2000","unstructured":"Touw D, Graafland O, Cranendonk A, Vermeulen R, Van Weissenbruch M (2000) Clinical pharmacokinetics of phenobarbital in neonates. Eur J Pharm Sci 12(2):111\u2013116","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"3011_CR8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00003088-197601030-00001","volume":"1","author":"EF Hvidberg","year":"1976","unstructured":"Hvidberg EF, Dam M (1976) Clinical pharmacokinetics of anticonvulsants. Clin Pharmacokinet 1(3):161\u2013188","journal-title":"Clin Pharmacokinet"},{"key":"3011_CR9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000457158","volume":"7","author":"S Onishi","year":"1984","unstructured":"Onishi S, Ohki Y, Nishimura Y, Itoh S, Isobe K, Hosoe A, Yamamoto T, Yamakawa T (1984) Distribution of phenobarbital in serum, brain and other organs from pediatric patients. Dev Pharmacol Ther 7:153\u2013159","journal-title":"Dev Pharmacol Ther"},{"issue":"9","key":"3011_CR10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.31.9.1107","volume":"31","author":"M Painter","year":"1981","unstructured":"Painter M, Pippenger C, Wasterlain C, Barmada M, Pitlick W, Carter G et al (1981) Phenobarbital and phenytoin in neonatal seizures: metabolism and tissue distribution. Neurology 31(9):1107","journal-title":"Neurology"},{"issue":"5","key":"3011_CR11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1345\/aph.17332","volume":"32","author":"GD Anderson","year":"1998","unstructured":"Anderson GD (1998) A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 32(5):554\u2013563","journal-title":"Ann Pharmacother"},{"issue":"6","key":"3011_CR12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2165\/00003088-199631060-00005","volume":"31","author":"R Riva","year":"1996","unstructured":"Riva R, Albani F, Contin M, Baruzzi A (1996) Pharmacokinetic interactions between antiepileptic drugs. Clin Pharmacokinet 31(6):470\u2013493","journal-title":"Clin Pharmacokinet"},{"issue":"11\u201312","key":"3011_CR13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s002280050703","volume":"55","author":"K Mamiya","year":"2000","unstructured":"Mamiya K, Hadama A, Yukawa E, Ieiri I, Otsubo K, Ninomiya H, Tashiro N, Higuchi S (2000) CYP2C19 polymorphism effect on phenobarbitone. Pharmacokineties in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol 55(11\u201312):821\u2013825","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3011_CR14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/FTD.0b013e318030def0","volume":"29","author":"S Goto","year":"2007","unstructured":"Goto S, Seo T, Murata T, Nakada N, Ueda N, Ishitsu T, Nakagawa K (2007) Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese. Ther Drug Monit 29(1):118\u2013121","journal-title":"Ther Drug Monit"},{"issue":"9","key":"3011_CR15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.2042-7158.1992.tb05514.x","volume":"44","author":"E Yukawa","year":"1992","unstructured":"Yukawa E, Higuchi S, Aoyama T (1992) Phenobarbitone population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. J Pharm Pharmacol 44(9):755\u2013760","journal-title":"J Pharm Pharmacol"},{"issue":"5","key":"3011_CR16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF00194954","volume":"48","author":"JH Botha","year":"1995","unstructured":"Botha JH, Gray AL, Miller R (1995) Determination of phenobarbitone population clearance values for South African children. Eur J Clin Pharmacol 48(5):381\u2013383","journal-title":"Eur J Clin Pharmacol"},{"issue":"5\u20136","key":"3011_CR17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2710.1997.tb00023.x","volume":"22","author":"E Chan","year":"1997","unstructured":"Chan E, Chan K, Teoh R (1997) Determination of phenobarbitone population clearance values for physically and mentally handicapped Chinese children with epilepsy. J Clin Pharm Ther 22(5\u20136):399\u2013403","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"3011_CR18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s002280050423","volume":"54","author":"E Yukawa","year":"1998","unstructured":"Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T (1998) Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling. Eur J Clin Pharmacol 54(1):69\u201374","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"3011_CR19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2710.2005.00619.x","volume":"30","author":"E Yukawa","year":"2005","unstructured":"Yukawa E, Suematsu F, Yukawa M, Minemoto M (2005) Population pharmacokinetic investigation of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants. J Clin Pharm Ther 30(2):159\u2013163","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"3011_CR20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2710.2006.00712.x","volume":"31","author":"E Yukawa","year":"2006","unstructured":"Yukawa E, Mamiya K (2006) Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using non-linear mixed effects model approach. J Clin Pharm Ther 31(3):275\u2013282","journal-title":"J Clin Pharm Ther"},{"issue":"1\u20132","key":"3011_CR21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1440-1754.2009.01611.x","volume":"46","author":"JM Wilmshurst","year":"2010","unstructured":"Wilmshurst JM, Van Der Walt JS, Ackermann S, Karlsson MO, Blockman M (2010) Rescue therapy with high-dose oral phenobarbitone loading for refractory status epilepticus. J Paediatr Child Health 46(1\u20132):17\u201322","journal-title":"J Paediatr Child Health"},{"issue":"6","key":"3011_CR22","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1365-2710.2010.01220.x","volume":"36","author":"M Yukawa","year":"2011","unstructured":"Yukawa M, Yukawa E, Suematsu F, Takiguchi T, Ikeda H, Aki H, Mimemoto M (2011) Population pharmacokinetics of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants: an update. J Clin Pharm Ther 36(6):704\u2013710","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"3011_CR23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/archdischild-2011-300538","volume":"97","author":"SM Lee","year":"2012","unstructured":"Lee SM, Chung JY, Lee YM, Park MS, Namgung R, Park KI, Lee C (2012) Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures. Arch Dis Child 97(6):569\u2013572","journal-title":"Arch Dis Child"},{"issue":"24","key":"3011_CR24","first-page":"103","volume":"147","author":"MPH Van Den Broek","year":"2012","unstructured":"Van Den Broek MPH, Huitema ADR, Groenendaal F, Van Straaten HLM, Toet M, Egberts ACG et al (2012) Pharmacokinetics and pharmacodynamics of phenobarbital during therapeutic hypothermia in asphyxiated newborns. Pharmaceutisch Weekblad 147(24):103\u2013106","journal-title":"Pharmaceutisch Weekblad"},{"issue":"2","key":"3011_CR25","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/PCC.0b013e31825bbbc2","volume":"14","author":"RA Shellhaas","year":"2013","unstructured":"Shellhaas RA, Ng CM, Dillon CH, Barks JDE, Bhatt-Mehta V (2013) Population pharmacokinetics of phenobarbital in infants with neonatal encephalopathy treated with therapeutic hypothermia. Pediatr Crit Care Med 14(2):194\u2013202","journal-title":"Pediatr Crit Care Med"},{"key":"3011_CR26","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.ejps.2017.05.026","volume":"109","author":"S V\u00f6ller","year":"2017","unstructured":"V\u00f6ller S, Flint RB, Stolk LM, Degraeuwe PLJ, Simons SHP, Pokorna P, Burger DM, de Groot R, Tibboel D, Knibbe CAJ (2017) Model-based clinical dose optimization for phenobarbital in neonates: an illustration of the importance of data sharing and external validation. Eur J Pharm Sci 109:S90\u2013SS7","journal-title":"Eur J Pharm Sci"},{"issue":"7","key":"3011_CR27","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/epi.14447","volume":"59","author":"BS Moffett","year":"2018","unstructured":"Moffett BS, Weingarten MM, Galati M, Placencia JL, Rodman EA, Riviello JJ, Kayyal SY (2018) Phenobarbital population pharmacokinetics across the pediatric age spectrum. Epilepsia. 59(7):1327\u20131333","journal-title":"Epilepsia."},{"issue":"2","key":"3011_CR28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00228-014-1778-7","volume":"71","author":"K Vu\u010di\u0107evi\u0107","year":"2015","unstructured":"Vu\u010di\u0107evi\u0107 K, Jovanovi\u0107 M, Golubovi\u0107 B, Kova\u010devi\u0107 SV, Miljkovi\u0107 B, Martinovi\u0107 \u017d, Prostran M (2015) Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. Eur J Clin Pharmacol 71(2):183\u2013190","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"3011_CR29","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bcp.13510","volume":"84","author":"J Methaneethorn","year":"2018","unstructured":"Methaneethorn J (2018) A systematic review of population pharmacokinetics of valproic acid. Br J Clin Pharmacol 84(5):816\u2013834","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3011_CR30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s13318-017-0421-2","volume":"43","author":"J Methaneethorn","year":"2018","unstructured":"Methaneethorn J (2018) Population pharmacokinetic analyses of lithium: a systematic review. Eur J Drug Metab Pharmacokinet 43(1):25\u201334","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"6","key":"3011_CR31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000457062","volume":"8","author":"TH Grasela Jr","year":"1985","unstructured":"Grasela TH Jr, Donn SM (1985) Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. Dev Pharmacol Ther 8(6):374\u2013383","journal-title":"Dev Pharmacol Ther"},{"issue":"4","key":"3011_CR32","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/fcp.12042","volume":"28","author":"A Marsot","year":"2014","unstructured":"Marsot A, Brevaut-Malaty V, Vialet R, Boulamery A, Bruguerolle B, Simon N (2014) Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach. Fundam Clin Pharmacol 28(4):465\u2013471","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"3011_CR33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00003088-200746030-00003","volume":"46","author":"K Brendel","year":"2007","unstructured":"Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B et al (2007) Are population pharmacokinetic and\/or pharmacodynamic models adequately evaluated? Clin Pharmacokinet 46(3):221\u2013234","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"3011_CR34","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","volume":"54","author":"S Kanji","year":"2015","unstructured":"Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, Edwards S, Ensom MHH, Foster DR, Hardy B, Kiser TH, la Porte C, Roberts JA, Shulman R, Walker S, Zelenitsky S, Moher D (2015) Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement. Clin Pharmacokinet 54(7):783\u2013795","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"3011_CR35","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2125.2007.02975.x","volume":"64","author":"C Dartois","year":"2007","unstructured":"Dartois C, Brendel K, Comets E, Laffont C, Laveille C, Tranchand B et al (2007) Overview of model-building strategies in population PK\/PD analyses: 2002\u20132004 literature survey. Br J Clin Pharmacol 64(5):603\u2013612","journal-title":"Br J Clin Pharmacol"},{"key":"3011_CR36","doi-asserted-by":"crossref","unstructured":"Abdel-Jalil M, Abdullah N, Alsous M, Saleh M, Abu-Hammour K (2020) A systematic review of population pharmacokinetic analyses of digoxin in the pediatric population. Br J Clin Pharmacol","DOI":"10.1111\/bcp.14272"},{"issue":"1","key":"3011_CR37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0306-3623(81)90028-8","volume":"12","author":"PN Patsalos","year":"1981","unstructured":"Patsalos PN, Lascelles PT (1981) Inhibition of in vitro diphenylhydantoin hydroxylation by different anticonvulsant drug combinations: a kinetic analysis. General Pharmacology: The Vascular System 12(1):51\u201355","journal-title":"General Pharmacology: The Vascular System"},{"issue":"1","key":"3011_CR38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1749-6632.1971.tb46892.x","volume":"179","author":"P Morselli","year":"1971","unstructured":"Morselli P, Rizzo M, Garattini S (1971) Interaction between phenobarbital and diphenylhydantoin in animals and in epileptic patients. Ann N Y Acad Sci 179(1):88\u2013107","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"3011_CR39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0028-2243(94)90245-3","volume":"54","author":"R Manganaro","year":"1994","unstructured":"Manganaro R, Mam\u00ec C, Gemelli M (1994) The validity of the Apgar scores in the assessment of asphyxia at birth. European Journal of Obstetrics & Gynecology and Reproductive Biology 54(2):99\u2013102","journal-title":"European Journal of Obstetrics & Gynecology and Reproductive Biology"},{"issue":"4","key":"3011_CR40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF00607431","volume":"12","author":"G Heimann","year":"1977","unstructured":"Heimann G, Gladtke E (1977) Pharmacokinetics of phenobarbital in childhood. Eur J Clin Pharmacol 12(4):305\u2013310","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"3011_CR41","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1172\/JCI103518","volume":"36","author":"WJ Waddell","year":"1957","unstructured":"Waddell WJ, Butler TC (1957) The distribution and excretion of phenobarbital. J Clin Invest 36(8):1217\u20131226","journal-title":"J Clin Invest"},{"key":"3011_CR42","doi-asserted-by":"crossref","unstructured":"(2015) The Apgar Score. Pediatrics 136(4):819\u2013822","DOI":"10.1542\/peds.2015-2651"},{"issue":"2","key":"3011_CR43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00003088-197601020-00001","volume":"1","author":"PL Morselli","year":"1976","unstructured":"Morselli PL (1976) Clinical pharmacokinetics in neonates. Clin Pharmacokinet 1(2):81\u201398","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3011_CR44","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/adc.57.4.283","volume":"57","author":"GW Rylance","year":"1982","unstructured":"Rylance GW, Moreland TA, Cowan MD, Clark DC (1982) Liver volume estimation using ultrasound scanning. Arch Dis Child 57(4):283\u2013286","journal-title":"Arch Dis Child"},{"issue":"4","key":"3011_CR45","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0022-3476(85)80097-4","volume":"106","author":"K Chiba","year":"1985","unstructured":"Chiba K, Suganuma T, Ishizaki T, Iriki T, Shirai Y, Naitoh H, Hori M (1985) Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment. J Pediatr 106(4):653\u2013658","journal-title":"J Pediatr"},{"issue":"2","key":"3011_CR46","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0022-3476(81)80488-X","volume":"99","author":"T Suganuma","year":"1981","unstructured":"Suganuma T, Ishizaki T, Chiba K, Hori M (1981) The effect of concurrent administration of valproate sodium on phenobarbital plasma concentration\/dosage ratio in pediatric patients. J Pediatr 99(2):314\u2013317","journal-title":"J Pediatr"},{"issue":"4","key":"3011_CR47","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/clpt.1981.66","volume":"29","author":"IM Kapetanovic","year":"1981","unstructured":"Kapetanovic IM, Kupferberg HJ, Porter RJ, Theodore W, Schulman E, Penry JK (1981) Mechanism of valproate-phenobarbital interaction in epileptic patients. Clin Pharmacol Ther 29(4):480\u2013486","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3011_CR48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/bdd.2510140108","volume":"14","author":"M Pokrajac","year":"1993","unstructured":"Pokrajac M, Miljkovi\u0107 B, Varagi\u0107 VM, Levi\u0107 Z (1993) Pharmacokinetic interaction between valproic acid and phenobarbital. Biopharm Drug Dispos 14(1):81\u201386","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"3011_CR49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2165\/00002018-199309030-00003","volume":"9","author":"PN Patsalos","year":"1993","unstructured":"Patsalos PN, Duncan JS (1993) Antiepileptic drugs. Drug Saf 9(3):156\u2013184","journal-title":"Drug Saf"},{"issue":"7982","key":"3011_CR50","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0140-6736(76)92405-3","volume":"308","author":"D Lambie","year":"1976","unstructured":"Lambie D, Johnson R, Nanda R, Shakir R (1976) Therapeutic and pharmacokinetic effects of increasing phenytoin in chronic epileptics on multiple drug therapy. Lancet 308(7982):386\u2013389","journal-title":"Lancet"},{"issue":"5","key":"3011_CR51","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2125.1977.tb00783.x","volume":"4","author":"M Eadie","year":"1977","unstructured":"Eadie M, Lander C, Hooper W, Tyrer J (1977) Factors influencing plasma phenobarbitone levels in epileptic patients. Br J Clin Pharmacol 4(5):541\u2013547","journal-title":"Br J Clin Pharmacol"},{"issue":"20","key":"3011_CR52","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/0006-2952(77)90168-X","volume":"26","author":"PN Patsalos","year":"1977","unstructured":"Patsalos PN, Lascelles PT (1977) In vitro hydroxylation of diphenylhydantoin and its inhibition by other commonly used anticonvulsant drugs. Biochem Pharmacol 26(20):1929\u20131933","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"3011_CR53","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/cpt1975186733","volume":"18","author":"JJ Cereghino","year":"1975","unstructured":"Cereghino JJ, Brock JT, Van Meter JC, Penry JK, Smith LD, White BG (1975) The efficacy of carbamazepine combinations in epilepsy. Clinical Pharmacology & Therapeutics 18(6):733\u2013741","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"2","key":"3011_CR54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/(SICI)1099-081X(199603)17:2<155::AID-BDD944>3.0.CO;2-R","volume":"17","author":"S Sennoune","year":"1996","unstructured":"Sennoune S, Iliadis A, Bonneton J, Barra Y, Genton P, Mesdjian E (1996) Steady state pharmacokinetics of carbamazepine-phenobarbital interaction in patients with epilepsy. Biopharm Drug Dispos 17(2):155\u2013164","journal-title":"Biopharm Drug Dispos"},{"key":"3011_CR55","unstructured":"Guelen PJM, van der Kleijn E (1978) Rational anti-epileptic drug therapy. Elsevier\/North-Holland Biomedical Press"},{"issue":"5","key":"3011_CR56","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/bja\/73.5.658","volume":"73","author":"C Wandel","year":"1994","unstructured":"Wandel C, Bocker R, Bohrer H, Browne A, Rugheimer E, Martin E (1994) Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 73(5):658\u2013661","journal-title":"Br J Anaesth"},{"issue":"8","key":"3011_CR57","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","volume":"32","author":"X-Q Li","year":"2004","unstructured":"Li X-Q, Andersson TB, Ahlstr\u00f6m M, Weidolf L (2004) Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32(8):821\u2013827","journal-title":"Drug Metab Dispos"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03011-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-03011-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03011-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T05:31:11Z","timestamp":1634621471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-03011-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["3011"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-03011-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,19]]},"assertion":[{"value":"17 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts of interest that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}